Spike Protein News and Research

RSS

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.

2 Aug 2021

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Researchers in the United States have conducted a study showing the difference in antibody evolution following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between people who have not previously been infected with the virus and those who have.

1 Aug 2021

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

A new study published on the bioRxiv* preprint server used molecular phylogenetic analysis to study the evolutionary trait of the Lambda variant.

30 Jul 2021

SARS-CoV-2 interacts with sialic acid cell surface glycans

In a paper recently uploaded to the journal Frontiers in Chemistry by Li et al. (July 22nd, 2021) the interaction between the SARS-CoV-2 spike protein and N-acetylneuraminic acid (NANA), the most commonly found sialic acid in humans, is investigated, finding that the molecule may act as a secondary or supplementary receptor to the virus.

30 Jul 2021

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Nanocovax is a protein subunit vaccine that contains the full-length spike stabilized by the addition of two prolines

29 Jul 2021

Study explains how SARS-CoV-2 variants differ in binding to ACE2 receptor

The current study explored ACE2-RBD interactions with four VoCs including the Alpha, Beta, Gamma, and Delta variants.

29 Jul 2021

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Researchers in the United States have provided important insights into the antigen-specific cellular response and evolving humoral (antibody) response to messenger RNA- (mRNA) based vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

29 Jul 2021

Mass spectrometry used to develop N-glycosylation profiles for SARS-CoV-2 D614G

A new study has characterized and compared the N-glycosylation of the wild type (S-614D) and variant (S-614G) of SARS-CoV-2 S glycoproteins using MS techniques.

28 Jul 2021

Mini-antibodies efficiently block SARS-CoV-2 virus

Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants.

28 Jul 2021

Unraveling the mysterious mutations that make delta the most transmissible covid virus yet

Upon first inspection, the mutations in the highly contagious delta covid variant don't look that worrisome.

28 Jul 2021

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

A study analyzes the immune responses of medical personnel, as well as immunocompromised DP and immunosuppressed KTR patients.

27 Jul 2021

SARS-CoV-2 spike-specific antibodies induced in breast milk by COVID-19 vaccines

An interesting new paper examines how these vaccines can help young patient populations to withstand the virus.

27 Jul 2021

Study suggests mRNA SARS-CoV-2 vaccines remain effective against variants

A study reports that many VOCs are associated with impaired reduction in their susceptibility to neutralization by COVID-19 vaccines.

27 Jul 2021

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A Korean study has recently demonstrated antiviral potency of monoclonal antibody CT-P59 against the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The experiments conducted in animals infected with the delta variant have shown that CT-P59 is able to reduce symptom intensity and viral replication in the respiratory tract. The study is currently available on the bioRxiv* preprint server.

27 Jul 2021

How SARS-CoV-2 vaccination symptoms differ from early COVID-19 symptoms

A new study published on the preprint server medRxiv* presents an analysis of the differences between recorded vaccination side effects vs. early COVID-19 symptoms. The researchers focused on four vaccines, namely, Pfizer-BioNTech (PB) mRNA (BNT162b2) vaccine, based on messenger ribonucleic acid encoding the viral spike protein; the Moderna mRNA (mRNA-1273) vaccine; the Oxford-AstraZeneca (O-AZ) adenovirus-vectored vaccine; and the Janssen adenovirus-vectored Ad26.COV2.S).

26 Jul 2021

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

In a research paper recently uploaded to the preprint server bioRxiv by Tada et al. (July 19th, 2021) the neutralizing capacity of antibodies generated by either messenger RNA (mRNA) or adenoviral vector-based vaccines against Beta, Delta, Delta plus, and Lambda variants are investigated, among others, highlighting the importance of continued SARS-CoV-2 genomic surveillance.

26 Jul 2021

Spike Protein News and Research

Pfizer moves towards an oral anti-COVID-19 therapy

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

SARS-CoV-2 interacts with sialic acid cell surface glycans

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Study explains how SARS-CoV-2 variants differ in binding to ACE2 receptor

Study reveals cellular basis of antigen-specific response to Pfizer-BioNTech’s COVID-19 vaccine

Mass spectrometry used to develop N-glycosylation profiles for SARS-CoV-2 D614G

Mini-antibodies efficiently block SARS-CoV-2 virus

Unraveling the mysterious mutations that make delta the most transmissible covid virus yet

Immunity to SARS-CoV-2 in renal transplant and dialysis patients using Pfizer/BioNTech and Moderna vaccines

SARS-CoV-2 spike-specific antibodies induced in breast milk by COVID-19 vaccines

Study suggests mRNA SARS-CoV-2 vaccines remain effective against variants

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

How SARS-CoV-2 vaccination symptoms differ from early COVID-19 symptoms

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News